Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Design, Synthesis and In Combo Antidiabetic Bioevaluation of Multitarget Phenylpropanoic Acids

Blanca Colín-Lozano
,
Samuel Estrada-Soto
ORCID logo ,
Fabiola Chávez-Silva
,
Abraham Gutiérrez-Hernández
,
Litzia Cerón-Romero
,
Abraham Giacoman-Martínez
,
Julio Cesar Almanza-Pérez
,
Emanuel Hernández-Núñez
ORCID logo ,
Zhilong Wang
,
Xin Xie
,
Mario Cappiello
,
Francesco Balestri
,
Umberto Mura
ORCID logo ,
Gabriel Navarrete Vázquez
* ORCID logo
Version 1 : Received: 8 January 2018 / Approved: 9 January 2018 / Online: 9 January 2018 (08:54:18 CET)

A peer-reviewed article of this Preprint also exists.

Colín-Lozano, B.; Estrada-Soto, S.; Chávez-Silva, F.; Gutiérrez-Hernández, A.; Cerón-Romero, L.; Giacoman-Martínez, A.; Almanza-Pérez, J.C.; Hernández-Núñez, E.; Wang, Z.; Xie, X.; Cappiello, M.; Balestri, F.; Mura, U.; Navarrete-Vazquez, G. Design, Synthesis and in Combo Antidiabetic Bioevaluation of Multitarget Phenylpropanoic Acids. Molecules 2018, 23, 340. Colín-Lozano, B.; Estrada-Soto, S.; Chávez-Silva, F.; Gutiérrez-Hernández, A.; Cerón-Romero, L.; Giacoman-Martínez, A.; Almanza-Pérez, J.C.; Hernández-Núñez, E.; Wang, Z.; Xie, X.; Cappiello, M.; Balestri, F.; Mura, U.; Navarrete-Vazquez, G. Design, Synthesis and in Combo Antidiabetic Bioevaluation of Multitarget Phenylpropanoic Acids. Molecules 2018, 23, 340.

Abstract

We synthesized a small series of five 3-[4-arylmethoxy)phenyl]propanoic acids using an easy and short step synthetic route. All compounds were tested in vitro against a set of four protein targets identified as key elements in diabetes: GPR40, aldose reductase (AKR1B1), PPARγ and GLUT-4. Compound 1 displayed an EC50 value of 0.075 μM against GPR40 and was an AKR1B1 inhibitor, showing IC50 = 7.4 μM. Compounds 2 and 3 behave as AKR1B1 inhibitors, GPR40 agonists and showed an increase of 2 to 4-times in the mRNA expression of PPARγ, as well as the GLUT-4 levels. Docking studies were conducted in order to explain the polypharmacological mode of action and the interaction binding mode of the most active compounds on these targets. Compounds 1-3 were tested in vivo at 100 mg/kg dose, being 2 and 3 orally actives, reducing glucose levels in a non insulin-dependent diabetes mellitus mice model. Compounds 2 and 3 showed robust in vitro and in vivo efficacy, and could be considered as promising multitarget antidiabetic drug candidates. This is the first report of a single molecule with these four polypharmacological target action.

Keywords

Diabetes; GPR40; AKRB1; PPARγ; GLUT-4

Subject

Chemistry and Materials Science, Medicinal Chemistry

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.